Hydrogen Therapy Shows Promise for Reducing Deadly Cell Inflammation
- Authors
- Yong Ye, Zi-Hang Yu, Liang Nie, Bin Lu, Guo Mu
- Journal
- Molecular Biology Reports
- Year
- 2025
- DOI
- 10.1007/s11033-025-10757-z
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Cardiac Ischemia-Reperfusion Injury
- Body System
- Cardiovascular
TL;DR
Scientists discovered that hydrogen gas might be a powerful new medicine that can stop harmful inflammation in the body by blocking a type of cell death that causes lots of damage, and interestingly, it could even help fight cancer by letting tumor cells die while protecting healthy cells.
Key Finding
Molecular hydrogen appears to regulate pyroptosis through multiple interconnected mechanisms including gasdermin modification and inflammasome disruption, with preclinical evidence suggesting cytoprotective effects in normal tissues and potential anti-cancer effects in malignant cells.
Summary
This review examines how molecular hydrogen may regulate pyroptosis, a type of inflammatory cell death that contributes to various diseases. Researchers found that hydrogen appears to work through multiple mechanisms, including modifying gasdermin proteins and disrupting inflammasome assembly (structures that trigger inflammation). In animal studies, hydrogen showed protective effects in normal tissues while potentially promoting cell death in cancer cells, but the review notes that moving this research to human treatments requires better delivery methods, standardized dosing, and reliable biomarkers to measure effects.
Practical Takeaway
While this review summarizes promising preclinical research on hydrogen's potential to regulate pyroptosis-related diseases, it is a literature review rather than a new clinical study, and the authors explicitly note that significant barriers remain before human applications. The evidence is currently limited to animal and laboratory studies; human clinical trials are needed before any therapeutic claims can be made.
Abstract
Pyroptosis, a highly inflammatory programmed cell death pathway, drives pathogenesis in numerous diseases through gasdermin-mediated membrane pore formation and massive cytokine release. While conventional anti-inflammatory therapies show limited efficacy, hydrogen emerges as a novel therapeutic agent with unique pyroptosis-regulatory capabilities. This review establishes a comprehensive mechanistic framework demonstrating that hydrogen modulates pyroptosis through interconnected pathways including direct gasdermin redox modification, mitochondrial signaling integration, and inflammasome assembly disruption. Systematic analysis across diverse disease models-cardiac ischemia-reperfusion, neuroinflammation, metabolic dysfunction, and cancer-reveals hydrogen's remarkable context-dependent effects: cytoprotective in normal tissues while promoting therapeutic pyroptosis in malignant cells. Hydrogen's regulatory mechanisms exhibit striking tissue specificity and temporal complexity, with immediate antioxidant effects transitioning to sustained anti-inflammatory responses. Despite compelling preclinical evidence demonstrating efficacy in myocardial injury, neurodegeneration, and systemic inflammation, significant translational barriers remain including delivery optimization, dosimetric standardization, and biomarker development. This review critically evaluates hydrogen's transformative therapeutic potential while addressing realistic implementation challenges, providing a roadmap for advancing this innovative paradigm from bench to bedside.